Desogestrel Contraceptives: 1.6 Million French Women Warned of Tumour Risk
ANSM says the risk rises with longer use and remains low, while letters will go to 1.6 million women and leaflets are being updated.
28 Articles
28 Articles
The ANSM Department advises affected patients to seek medical advice in case of suspected symptoms, such as persistent headaches, visual disturbances or memory gaps.
Notice to 1.6 million women who have taken the pill for “very weak risk” of developing meningioma
The 75 μg deogestrel-based pills present a low risk of tumours in the brain. 1.6 million French people who have used these pills will receive a letter from the National Drug Security Agency...
Desogestrel contraceptives: 1.6 million French women warned of tumour risk
The French medicines agency (ANSM) urges women who take desogestrel contraceptives to seek medical advice if they develop suggestive symptoms, such as persistent headaches, visual disturbances or memory loss.
An alert study on a "very low" risk of meningioma related to certain degestrel-based contraceptive pills. Here is a list of the pills, implants and contraceptive rings involved.
This concerns degestrel-based contraceptives such as Antigone, Cerazette, Elfasette, Optimizette pills...
Coverage Details
Bias Distribution
- 61% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
